Search Results

Xentria announces major milestone of first patient enrolled in The XTMAB16 Study evaluating TNFα inhibitor for the treatment of sarcoidosis.

Xentria Inc. and Meitheal Pharmaceuticals, Inc. announced an exclusive multi-year licensing agreement to commercialize its lead candidate, and novel biologic, XTMAB-16 for pulmonary sarcoidosis in North America.

Xentria Announces Peer Reviewed Publication of Biosimulation Model in Frontiers in Pharmacology Journal.

Xentria Inc. announced a $25 million growth equity funding round approved by its Board of Directors and the opening of a new corporate headquarters.

Xentria Inc., a biotech company focused on developing novel therapeutics to address unmet clinical needs, made key leadership appointments, naming Dr. Robert Baughman as Lead Scientific Advisor and Kirsten Anderson as Chief Operating Officer.

Xentria Inc., a biotech company focused on developing novel biologics to address unmet clinical needs, presented its first set of data showing its novel biologic, XTMAB-16, has the potential to reduce the formation of sarcoidosis granulomas.

Xentria Inc., a biotech company focused on developing novel biologics to address unmet clinical needs, announced that a new abstract showcasing XTMAB-16’s potential effect on sarcoidosis granuloma formation will be presented at the upcoming American Thoracic Society 2022 International Conference being held in San Francisco, CA from May 13-18, 2022.